Pain in the Leg

Last updated 1 Jun 2026 · Musculoskeletal / Vascular

📋 Key Information Summary

📋

Systematic approach essential: Leg pain has a broad differential spanning musculoskeletal, vascular, neurologic, and systemic causes — always apply a structured diagnostic model to avoid missing serious pathology.
Red-flag causes requiring urgent action: DVT (Wells score ≥2), compartment syndrome (the 6 Ps), acute limb ischaemia, cauda equina syndrome, and necrotising fasciitis must be excluded before attributing pain to benign aetiology.
Sciatica affects approximately 5–10% of Australians with low back pain and is most commonly caused by lumbar disc herniation (L4–S1) compressing the sciatic nerve root.
Neurogenic vs vascular claudication: Neurogenic claudication improves with spinal flexion (sitting, leaning forward) and has a variable walking distance; vascular claudication is exercise-proportional, improves with standing rest, and is associated with absent peripheral pulses.
DVT: Wells score ≥2 combined with a negative D-dimer effectively excludes DVT in the outpatient setting; a score ≥2 mandates compression ultrasonography. D-dimer has limited specificity in hospitalised, elderly, post-operative, and pregnant patients.
Compartment syndrome is a surgical emergency — clinical diagnosis (pain out of proportion, pain with passive stretch, paraesthesia) takes priority over compartment pressure measurements; fasciotomy must not be delayed for imaging.
Peripheral arterial disease (PAD) affects ~12% of Australians aged ≥65 years; ABI <0.9 is diagnostic. First-line management includes supervised exercise, smoking cessation, antiplatelet therapy (aspirin 100 mg daily or clopidogrel 75 mg daily), and lipid-lowering with atorvastatin 40–80 mg daily.
Nerve entrapment syndromes include meralgia paraesthetica (lateral femoral cutaneous nerve), tarsal tunnel syndrome (posterior tibial nerve), and peroneal nerve palsy at the fibular head — each with distinct sensory distributions and provocative tests.
Pharmacological management of sciatica: First-line with paracetamol ± NSAIDs; consider gabapentinoids (pregabalin 75 mg BD, titrate) or duloxetine 60 mg daily for neuropathic component; oral corticosteroid short courses have limited evidence. Epidural corticosteroid injections may be considered for refractory radicular pain.
DVT treatment: DOACs (apixaban 10 mg BD × 7 days then 5 mg BD, or rivaroxaban 15 mg BD × 21 days then 20 mg daily) are first-line over warfarin for most patients; LMWH (enoxaparin 1 mg/kg SC BD) preferred in severe renal impairment (eGFR <15), antiphospholipid syndrome, or pregnancy.
Aboriginal and Torres Strait Islander populations have a higher burden of PAD, diabetes-related foot disease, and delayed presentations — culturally safe assessment, point-of-care testing, and community-based vascular screening are essential.

Introduction & Australian Epidemiology

Leg pain is one of the most common presenting complaints in Australian primary care and emergency medicine, accounting for an estimated 5–8% of all general practice consultations. The differential diagnosis is broad, encompassing musculoskeletal, vascular, neurologic, infectious, and systemic aetiologies. A structured diagnostic approach is critical because several life-threatening conditions — including deep vein thrombosis (DVT), acute limb ischaemia, compartment syndrome, and necrotising fasciitis — can masquerade as benign musculoskeletal pain.

In Australia, the burden of leg pain is significant:

Sciatica and radiculopathy: Lifetime prevalence of sciatica in Australia is estimated at 5–10% among adults with low back pain. Lumbar disc herniation accounts for the majority of cases, most commonly at L4–L5 and L5–S1.
Peripheral arterial disease (PAD): Affects approximately 12% of Australians aged ≥65 years and is frequently under-recognised. The Australian Institute of Health and Welfare (AIHW) reports PAD-related hospitalisations have risen in parallel with diabetes prevalence.
DVT: Venous thromboembolism (VTE) incidence in Australia is approximately 63 per 100,000 person-years. Hospital-acquired VTE remains a major patient safety concern under the ACSQHC National Safety and Quality Health Service Standards.
Sports and musculoskeletal injuries: Hamstring strains, calf tears, and Achilles tendon pathology are extremely common, particularly in Australian Rules football, rugby codes, running, and recreational sport.
Aboriginal and Torres Strait Islander populations: Experience disproportionately higher rates of diabetes-related peripheral neuropathy, lower-limb amputation, and delayed diagnosis of vascular disease.

⚠️

Clinical pearl: Never assume leg pain is "just a muscle" without first considering DVT, acute limb ischaemia, and compartment syndrome. A focused history and examination takes less than five minutes and can be life-saving.

Leg Pain Diagnostic Model

A systematic approach to leg pain should categorise the presentation by anatomical location, onset character (acute vs chronic), aggravating and relieving factors, and associated features. The following stepwise model is recommended for Australian primary care and emergency settings.

Identify Red Flags

Exclude immediately life-threatening causes: DVT (unilateral swelling, recent immobility/surgery, Wells ≥2), acute limb ischaemia (6 Ps: pain, pallor, pulselessness, paraesthesia, paralysis, poikilothermia), compartment syndrome (pain out of proportion, passive stretch pain, tense compartment), necrotising fasciolia (rapidly spreading erythema, crepitus, systemic toxicity), and cauda equina syndrome (saddle anaesthesia, urinary retention).

Characterise the Pain

Determine onset (sudden vs gradual), location (hip, thigh, knee, calf, ankle, foot, diffuse), quality (sharp, burning, aching, cramping), radiation pattern (dermatomal, non-dermatomal), and temporal profile (constant, intermittent, exercise-related, nocturnal).

Apply the VINDICATE Mnemonic

Vascular (DVT, PAD, chronic venous insufficiency, popliteal artery entrapment), Infection (cellulitis, necrotising fasciitis, osteomyelitis, septic arthritis), Neurological (sciatica, peripheral neuropathy, meralgia paraesthetica, nerve entrapment), Degenerative/inflammatory (osteoarthritis, rheumatoid arthritis, gout), Iatrogenic/idiopathic (drug-induced myopathy — statins, corticosteroid injection complications), Congenital (hip dysplasia, vascular malformations), Autoimmune (vasculitis, inflammatory myopathy), Trauma (fracture, muscle tear, tendon rupture), Endocrine/metabolic (hypothyroid myopathy, diabetic neuropathy, electrolyte disturbance).

Targeted Examination

Perform vascular assessment (peripheral pulses, ABI, capillary refill), neurological examination (myotomes, dermatomes, reflexes), musculoskeletal examination (range of motion, special tests — straight leg raise, femoral stretch test, Homan's sign), and compartment assessment if suspected.

Investigate & Refer

Order targeted investigations based on the clinical differential (see Investigations section). Arrange urgent vascular or orthopaedic referral where indicated. Provide safety-net advice for all patients discharged with a musculoskeletal diagnosis.

Location	Common Causes	Key Differentiators
Hip / groin	Osteoarthritis, femoral acetabular impingement, inguinal hernia, avascular necrosis, referred lumbar spine pathology	Groin pain with hip internal rotation suggests intra-articular pathology; pain with Valsalva suggests hernia
Anterior thigh	Femoral nerve radiculopathy (L3–L4), meralgia paraesthetica, quadriceps strain, femoral shaft stress fracture	Burning/tingling over lateral thigh = meralgia paraesthetica (lateral femoral cutaneous nerve entrapment)
Posterior thigh	Hamstring strain/tear, sciatica (L5–S1), ischial bursitis, proximal hamstring tendinopathy	Straight leg raise positive below 60° suggests sciatica; proximal hamstring tendinopathy worsened by sitting
Knee	Osteoarthritis, meniscal tear, ligament injury, patellofemoral pain, referred hip pathology, Baker's cyst	Always examine the hip in patients presenting with knee pain — hip pathology commonly refers to the knee
Calf	DVT, calf muscle strain/tear (gastrocnemius/soleus), popliteal (Baker's) cyst rupture, Achilles tendinopathy, vascular claudication, neurogenic claudication	Unilateral calf swelling mandates DVT exclusion; "pop" sensation = calf tear (tennis leg)
Ankle / foot	Ankle sprain, Achilles rupture, plantar fasciitis, tarsal tunnel syndrome, gout (1st MTP), Morton's neuroma, metatarsal stress fracture	Cannot tiptoe = Achilles rupture; pain worse in morning = plantar fasciitis; burning/tingling sole = tarsal tunnel
Diffuse / poorly localised	Restless legs syndrome, statin myopathy, peripheral neuropathy (diabetic, alcoholic), fibromyalgia, polymyalgia rheumatica, referred spinal pathology	Symmetrical burning/tingling in a stocking distribution = peripheral neuropathy; bilateral proximal pain + stiffness in >50 years = consider PMR/GCA

Sciatica & Nerve Entrapment

Sciatica (lumbosacral radiculopathy) refers to pain radiating from the lower back into the buttock and posterior leg, typically following a dermatomal distribution (most commonly L5 or S1). It is caused by compression or inflammation of a lumbar or sacral nerve root, most frequently due to a disc herniation at L4–L5 or L5–S1. Spinal canal stenosis, spondylolisthesis, and piriformis syndrome are less common causes.

ℹ️

Australian context: Sciatica affects approximately 5–10% of patients presenting with low back pain to Australian general practice. Most cases (80–90%) resolve with conservative management within 6–12 weeks. Early imaging is not recommended unless red flags are present (RACGP / NICE guidelines).

Clinical Features by Nerve Root Level

Nerve Root	Pain Distribution	Motor Deficit	Sensory Deficit	Reflex Change
L4	Anterior thigh and medial knee	Quadriceps weakness (difficulty with knee extension, stairs)	Medial calf	Patellar (knee jerk) diminished
L5	Lateral thigh, dorsum of foot, great toe	Extensor hallucis longus / tibialis anterior weakness (foot drop, difficulty heel-walking)	Dorsum of foot, first web space	Usually normal
S1	Posterior calf, lateral foot, sole	Gastrocnemius/soleus weakness (difficulty tiptoe-standing)	Lateral foot, sole	Ankle jerk diminished or absent

Red Flags Requiring Urgent Imaging / Referral

Cauda equina syndrome: saddle anaesthesia, urinary retention or incontinence, bilateral leg weakness, progressive neurological deficit
Significant or progressive motor deficit (e.g., foot drop — MRC grade ≤3)
Suspected spinal malignancy: unexplained weight loss, history of cancer, age >50 with first episode of sciatica, nocturnal pain unrelieved by rest
Suspected spinal infection: fever, IV drug use, immunosuppression, recent spinal procedure
Acute onset with severe pain and no response to conservative management at 6 weeks

🚨

Cauda equina syndrome is a surgical emergency. MRI of the lumbosacral spine must be performed within hours, and urgent neurosurgical or spinal surgical consultation is required. Do not delay for pain management.

Management of Sciatica

Conservative (First-Line — 80–90% resolve within 6–12 weeks)

Patient education and reassurance — most disc herniations resorb spontaneously
Stay active — avoid prolonged bed rest (RACGP recommendation)
Physiotherapy referral — McKenzie method, neural mobilisation, core stabilisation
Analgesia: paracetamol 1 g QID PRN + naproxen 250–500 mg BD with food or ibuprofen 400–600 mg TDS (short course, ≤2 weeks)

💊

Pregabalin

Lyrica® · Gabapentinoid · Neuropathic pain modulator

Adult dose 75 mg PO BD, titrate to 150–300 mg BD over 1–2 weeks

Paediatric dose Not recommended <18 years for this indication

Renal adjustment eGFR 30–60: max 75–150 mg BD; eGFR 15–30: 25–75 mg daily; eGFR <15: 25 mg daily

Key side effects Drowsiness, dizziness, weight gain, peripheral oedema, risk of dependence

PBS status Restricted Benefit — neuropathic pain (Authority Required)

💊

Duloxetine

Cymbalta® · SNRI · Neuropathic pain modulator

Adult dose 30 mg PO daily for 1 week, then 60 mg PO daily

Paediatric dose Not recommended for this indication in paediatrics

Renal adjustment Avoid if eGFR <30 mL/min

Hepatic adjustment Avoid in severe hepatic impairment

Key side effects Nausea, dry mouth, drowsiness, constipation; serotonin syndrome risk with concurrent SSRIs/MAOIs

PBS status Restricted Benefit — neuropathic pain (Authority Required)

💊

Gabapentin

Neurontin® · Gabapentinoid · Neuropathic pain modulator

Adult dose 300 mg PO daily (Day 1), 300 mg BD (Day 2), 300 mg TDS (Day 3), titrate to 300–600 mg TDS (max 3.6 g/day)

Renal adjustment eGFR 30–59: 200–700 mg BD; eGFR 15–29: 200–700 mg daily; eGFR <15: 100–300 mg daily

Key side effects Drowsiness, dizziness, ataxia, peripheral oedema

PBS status Restricted Benefit — neuropathic pain (Authority Required)

Interventional & Surgical

Epidural corticosteroid injection: Transforaminal or interlaminar approach may provide short-term (2–6 weeks) pain relief in refractory radicular pain. Evidence is modest; discuss risks (infection, bleeding, nerve injury). Refer to pain medicine or spinal specialist.
Surgery (microdiscectomy): Indicated for cauda equina syndrome (emergency), progressive motor deficit, or intractable sciatica not responding to ≥6–12 weeks of conservative management. Australian data (Surgical Treatment of Lumbar Disc Herniation trial) show modest benefit over continued conservative care at 1 year for intractable cases.

Nerve Entrapment Syndromes

Syndrome	Nerve	Site of Entrapment	Clinical Features	Management
Meralgia paraesthetica	Lateral femoral cutaneous nerve (L2–L3)	Inguinal ligament	Burning pain and paraesthesia over anterolateral thigh; worse with standing/walking, tight clothing; obesity, pregnancy, diabetes are risk factors	Weight loss, loose clothing, avoid tight belts; gabapentinoids; local corticosteroid injection; surgical decompression if refractory
Peroneal nerve palsy	Common peroneal nerve (L4–S1)	Fibular head	Foot drop, difficulty heel-walking; sensory loss over dorsum of foot and lateral leg; caused by leg-crossing, prolonged bed rest, cast compression, kneeling	Remove cause, ankle-foot orthosis (AFO), physiotherapy; nerve conduction studies if no recovery at 3 months; surgical exploration if traumatic laceration
Tarsal tunnel syndrome	Posterior tibial nerve	Medial ankle (behind medial malleolus)	Burning pain, tingling, and numbness in the sole of the foot; worse with prolonged standing/walking; Tinel's sign positive at medial ankle	Orthotics, activity modification, gabapentinoids; surgical decompression if conservative measures fail
Saphenous nerve entrapment	Saphenous nerve (L3–L4)	Adductor canal or medial knee	Aching pain and paraesthesia over medial knee and leg; worse with stairs, squatting; common after knee surgery	Physiotherapy, local anaesthetic/corticosteroid injection, neuromodulation for refractory cases

Neurogenic vs Vascular Claudication Comparison

Claudication — leg pain induced by walking — has two principal aetiologies: vascular (peripheral arterial disease) and neurogenic (lumbar spinal stenosis). Distinguishing between the two is critical because management pathways are fundamentally different. Misdiagnosis of vascular claudication as neurogenic may delay treatment of a potentially limb-threatening vascular condition.

⚠️

Important: The two conditions frequently coexist in elderly patients with concurrent cardiovascular disease and degenerative spinal disease. Always perform a vascular assessment (peripheral pulses, ABI) when evaluating any patient with exertional leg pain.

Feature	Vascular Claudication	Neurogenic Claudication
Underlying cause	Peripheral arterial disease (atherosclerosis)	Lumbar spinal stenosis (central canal narrowing)
Pain character	Cramping, aching, tightness in the calf (most common); may affect buttock or thigh with aortoiliac disease	Aching, heaviness, paraesthesia, or numbness; often bilateral; may involve buttocks, thighs, and calves
Reproducibility	Highly reproducible — occurs at a consistent walking distance on level ground	Variable — may depend on terrain (downhill/walking worse than uphill), uneven ground
Relieving factors	Standing still (rest) — pain resolves within minutes	Sitting, leaning forward, spinal flexion (shopping trolley sign) — pain resolves more slowly
Aggravating factors	Walking, especially uphill; cold weather	Walking, standing upright, spinal extension; walking downhill is worse than uphill
Postural effect	No significant postural component	Pronounced postural component — sitting improves, extension worsens
Peripheral pulses	Diminished or absent (posterior tibial, dorsalis pedis)	Usually normal (unless coexistent PAD)
ABI	<0.9 (diagnostic); <0.4 = critical limb ischaemia	Normal (≥0.9)
Neurological signs	Usually absent; late stages may have trophic changes	May have lower limb reflex changes, weakness, dermatomal sensory loss
Relief with standing	Yes — patient stops walking and stands still	No — must sit down or lean forward
Walking uphill	Worse (greater demand on calf muscles)	Paradoxically better (spinal flexion increases canal space)
Key investigation	ABI, duplex ultrasound, CT angiography	MRI lumbosacral spine (gold standard)
Definitive treatment	Supervised exercise, risk factor modification, endovascular revascularisation, surgical bypass	Physiotherapy, epidural injections, decompressive laminectomy

Peripheral Arterial Disease — Key Management Principles

Supervised exercise programme: 30–60 minutes, 3 times/week for ≥12 weeks — improves walking distance by 50–200% (strongest evidence for PAD symptom management). Refer to accredited exercise physiologist.
Smoking cessation: Single most important modifiable risk factor. Offer NRT, varenicline (Champix®), or bupropion (Zyban®) with behavioural support.
Antiplatelet therapy: Aspirin 100 mg daily or clopidogrel 75 mg daily (clopidogrel may be marginally superior in PAD-specific outcomes based on CAPRIE trial data).
Lipid-lowering: Atorvastatin 40–80 mg daily (target LDL-C <1.8 mmol/L for established PAD — PBS Authority Required for high-intensity statin at this target).
Blood pressure control: Target <130/80 mmHg; ACE inhibitor (perindopril 5–10 mg daily) preferred due to cardiovascular risk reduction data (HOPE trial).
Glycaemic control in diabetic patients with PAD — individualised HbA1c target.
Cilostazol (Pletal® 100 mg BD) — may improve walking distance; not PBS-listed in Australia; discuss with vascular specialist. Avoid in heart failure.

DVT & Compartment Syndrome

Deep Vein Thrombosis (DVT)

DVT is a potentially life-threatening condition that can lead to pulmonary embolism (PE), post-thrombotic syndrome, and chronic venous insufficiency. A structured diagnostic approach using clinical prediction rules, D-dimer, and compression ultrasonography is essential to avoid both missed diagnoses and unnecessary anticoagulation.

Wells Score for DVT

Criterion	Points
Active cancer (treatment within 6 months or palliative)	+1
Paralysis, paresis, or recent plaster immobilisation of the leg	+1
Recently bedridden >3 days or major surgery within 12 weeks	+1
Localised tenderness along the deep venous system	+1
Entire leg swollen	+1
Calf swelling >3 cm compared to asymptomatic leg (measured 10 cm below tibial tuberosity)	+1
Pitting oedema confined to symptomatic leg	+1
Collateral superficial veins (non-varicose)	+1
Previously documented DVT	+1
Alternative diagnosis at least as likely as DVT	−2

Low Risk

Wells Score ≤1

DVT prevalence ~5%. Perform high-sensitivity D-dimer. If negative → DVT effectively excluded. If positive → proceed to compression ultrasound.

Setting: GP / ED

Moderate

Wells Score 2–6

DVT prevalence ~17%. Perform high-sensitivity D-dimer. If negative → DVT effectively excluded. If positive → compression ultrasound.

Setting: ED / Vascular

High Risk

Wells Score ≥7

DVT prevalence ~53%. Proceed directly to compression ultrasonography — do not rely on D-dimer to exclude. If ultrasound negative, consider repeat US in 5–7 days or CT venography.

Setting: ED / Vascular / Haematology

⚠️

D-dimer limitations: D-dimer is highly sensitive but poorly specific. False positives are common in hospitalised patients, the elderly (>age-adjusted cutoffs apply: age × 10 ng/mL for patients >50 years), post-operative patients, pregnancy, malignancy, infection, and inflammatory conditions. Do not use D-dimer to exclude DVT in high-risk patients (Wells ≥2) — go straight to imaging.

DVT Treatment

💊

Apixaban

Eliquis® · DOAC (Factor Xa inhibitor)

Adult dose 10 mg PO BD × 7 days, then 5 mg PO BD for ≥3 months (first VTE); extended therapy if unprovoked: 2.5 mg BD

Renal adjustment eGFR <25: use with caution (reduced clearance); consider LMWH if eGFR <15

Hepatic adjustment Avoid in severe hepatic impairment (Child-Pugh C)

Key interactions Strong CYP3A4 / P-gp inhibitors (ketoconazole, ritonavir) — avoid; inducers (rifampicin, carbamazepine, phenytoin) — avoid

PBS status ✔ PBS General Benefit

💊

Rivaroxaban

Xarelto® · DOAC (Factor Xa inhibitor)

Adult dose 15 mg PO BD × 21 days, then 20 mg PO daily with food for ≥3 months (first VTE); extended: 10 mg daily

Renal adjustment eGFR 15–49: max 15 mg daily (after initial 21-day treatment); eGFR <15: avoid

Key interaction Must be taken with food (15 mg and 20 mg doses) for adequate absorption

PBS status ✔ PBS General Benefit

💊

Enoxaparin

Clexane® · LMWH

Adult dose 1 mg/kg SC BD (or 1.5 mg/kg SC daily)

Paediatric dose Age-dependent; neonates: 1.5 mg/kg SC BD; children: consult haematology dosing table

Renal adjustment eGFR <30: 1 mg/kg SC daily (monitor anti-Xa levels)

When to prefer LMWH over DOAC Severe renal impairment (eGFR <15), antiphospholipid syndrome, pregnancy, mechanical heart valve, extremes of body weight (<50 kg or >120 kg)

PBS status ✔ PBS General Benefit

Compartment Syndrome

Acute compartment syndrome (ACS) is a surgical emergency in which raised pressure within an osseofascial compartment compromises tissue perfusion, leading to ischaemia and potential permanent muscle and nerve damage. The lower leg is most commonly affected (anterior compartment most frequent). Without timely fasciotomy, irreversible tissue necrosis occurs within 6–8 hours.

🚨

Surgical emergency: Acute compartment syndrome requires emergent fasciotomy. Do not delay for compartment pressure measurements if clinical suspicion is high. The diagnosis is primarily clinical. Target door-to-fasciotomy time: <2 hours from decision.

The 6 Ps of Compartment Syndrome

Pain

Out of proportion to the injury. The earliest and most reliable sign. Not relieved by immobilisation or standard analgesia. Pain with passive stretch of the compartment muscles is highly specific.

Pressure

Tense, "wood-like" compartment on palpation. The compartment feels hard and non-compressible compared to the contralateral side.

Paraesthesia

Altered sensation in the distribution of nerves traversing the affected compartment. In the anterior compartment: deep peroneal nerve (first web space numbness).

Paralysis

Late sign — weakness of muscles within the compartment. Indicates advanced ischaemia and is an ominous finding.

Pallor

Late sign — pale or shiny skin over the compartment. Capillary refill may be prolonged. Less reliable than pain and pressure.

Pulselessness

Very late sign — indicates complete vascular occlusion. Peripheral pulses may still be present (compartment pressures rarely exceed arterial systolic pressure). A normal pulse does NOT exclude compartment syndrome.

⚠️

Pediatric consideration: Children cannot reliably report pain character and may become irritable or withdrawn. Compartment syndrome in children is most commonly associated with supracondylar fractures and forearm fractures. Maintain a high index of suspicion. Do not rely on pulselessness — it is a very late and unreliable sign in children.

Risk Factors for Compartment Syndrome

Tibial shaft fracture (most common cause — up to 40% of cases)
High-energy trauma (motor vehicle accidents, crush injuries)
Tight circumferential casts or dressings
Reperfusion after vascular repair or thrombolysis
Bleeding disorders or anticoagulation (spontaneous compartment haemorrhage)
Prolonged limb positioning (lithotomy position during surgery, drug overdose with limb compression)
Snakebite (particularly tiger snake and brown snake envenomation in Australia)

Compartment Pressure Measurement

When clinical assessment is unreliable (e.g., unconscious patient, regional anaesthesia, children), compartment pressure measurement may assist diagnosis:

Absolute pressure >30 mmHg within the compartment is concerning
Delta pressure (diastolic BP minus compartment pressure) <30 mmHg is the most sensitive threshold for fasciotomy
Continuous pressure monitoring (Stryker device or slit catheter) is preferred over single measurements
Clinical assessment should not be delayed for pressure measurement when suspicion is high

Risk Stratification & Severity Scoring

Effective risk stratification determines the urgency of investigation and treatment pathway. The following scoring tools are recommended for use in Australian emergency departments and primary care.

VTE Risk Stratification (Caprini Score — Surgical Patients)

All Australian hospitals are required under NSQHS Standards to assess VTE risk for every admitted patient using a validated risk assessment tool. The Caprini score is widely used in surgical populations, while the Padua Prediction Score is preferred for medical inpatients.

Limb Threat Assessment — Acute Limb Ischaemia (ALI)

Viable

Category I

No sensory or motor deficit. Doppler signals audible (arterial and venous). Urgent workup — not immediately limb-threatening.

Setting: Vascular ward

Threatened

Category IIa / IIb

IIa: Minimal sensory loss, no motor deficit. IIb: Sensory loss + mild-to-moderate motor deficit (can still wiggle toes). Requires urgent revascularisation within 6–24 hours.

Setting: Vascular surgery / interventional radiology

Irreversible

Category III

Profound sensory and motor deficit (anaesthetic, paralysed limb). Venous Doppler signals absent. Tissue death likely — amputation may be required even with revascularisation.

Setting: Emergency theatre / major amputation

Investigations

Investigations should be targeted to the clinical differential. Avoid blanket ordering of imaging for non-specific leg pain. The following investigations are recommended based on suspected aetiology, with Australian MBS item numbers noted where applicable.

Essential

FBE / CBC

Full blood count. Baseline for infection (raised WCC), anaemia (chronic disease), thrombocytopenia (HIT consideration). MBS Item 65060.

Essential

CRP / ESR

Inflammatory markers for infection, vasculitis, inflammatory myopathy, polymyalgia rheumatica. MBS Item 65070.

Essential

D-dimer (high-sensitivity)

For DVT exclusion in low-to-moderate risk patients (Wells ≤1). Age-adjusted cutoffs apply (>50 years: age × 10 ng/mL). Not useful if Wells ≥2. MBS Item 65143.

Available

Duplex Compression Ultrasonography

Gold standard for DVT diagnosis. Sensitivity >95% for proximal DVT; lower for distal (calf vein) DVT. Non-invasive, widely available in Australian EDs and radiology practices. MBS Item 55054.

Available

Ankle-Brachial Index (ABI)

ABI <0.9 is diagnostic for PAD. ABI 0.5–0.9 = mild-to-moderate claudication; <0.4 = critical limb ischaemia. ABI >1.3 suggests calcified vessels (diabetes, CKD) — perform toe-brachial index. MBS Item 11300.

Available

CT Angiography (CTA) — Lower Limb

For mapping PAD severity and planning revascularisation. Also used for suspected PE (CT pulmonary angiography). Contrast-enhanced — check renal function. MBS Item 56103.

Available

MRI Lumbosacral Spine

Gold standard for lumbar spinal stenosis, disc herniation, cauda equina syndrome. Not recommended for routine sciatica in the first 6 weeks without red flags. MBS Item 63242.

Available

Nerve Conduction Studies / EMG

For differentiating radiculopathy from peripheral neuropathy, confirming entrapment neuropathies (meralgia paraesthetica, peroneal palsy, tarsal tunnel). Best performed ≥3 weeks after symptom onset. MBS Item 11000.

Specialist

Compartment Pressure Measurement

For equivocal clinical compartment syndrome cases. Stryker device or slit catheter technique. Delta pressure (diastolic BP minus compartment pressure) <30 mmHg is the threshold. Usually performed by orthopaedic / vascular team.

Available

Musculoskeletal Ultrasound

For Achilles tendinopathy/rupture, calf muscle tears, Baker's cyst, soft tissue masses. Dynamic assessment capability. MBS Item 55800.

Directed Therapy & Management

Pharmacological Quick Reference

Sciatica (mild–moderate)

Paracetamol 1 g QID + Naproxen 250–500 mg BD

2–4 weeks; reassess

Add gabapentinoid if neuropathic component dominant

Sciatica (neuropathic dominant)

Pregabalin 75 mg BD → 300 mg BD OR Gabapentin 300 mg TDS → 600 mg TDS

Ongoing; reassess at 4 weeks

Duloxetine 60 mg daily as alternative; PBS Authority Required

DVT (unprovoked, first)

Apixaban 10 mg BD × 7 d then 5 mg BD

≥3 months; then consider indefinite

Rivaroxaban 15 mg BD × 21 d then 20 mg daily as alternative

DVT (provoked, transient risk factor)

Apixaban 10 mg BD × 7 d then 5 mg BD

3 months; usually ceases

Reassess VTE recurrence risk at end of treatment

PAD — symptom management

Supervised exercise programme + Aspirin 100 mg daily + Atorvastatin 40–80 mg daily

Long-term

Clopidogrel 75 mg daily as alternative to aspirin; Cilostazol 100 mg BD if refractory (specialist)

Compartment syndrome

Emergent fasciotomy (surgical)

Immediate

Elevate limb level with heart (not above); avoid ice; remove constrictive dressings; pre-op IV fluids

Non-Pharmacological Management

Physiotherapy: Core for sciatica (McKenzie method, neural mobilisation), PAD (supervised exercise), post-fasciotomy rehabilitation
Podiatry: Orthotics for tarsal tunnel syndrome, plantar fasciitis, metatarsalgia; diabetic foot care
Exercise physiology: Accredited exercise physiologists (AEP) for supervised exercise programmes in PAD — referral via GP Management Plan (MBS Item 721) and Team Care Arrangement (MBS Item 723)
Psychology: Chronic pain management — cognitive behavioural therapy (CBT), acceptance and commitment therapy (ACT); referral under Mental Health Treatment Plan (MBS Item 80110)
Weight management: Particularly relevant for meralgia paraesthetica, knee osteoarthritis, and PAD — referral to dietitian under GP Management Plan

Special Populations

🤰 Pregnancy

DVT risk: 4–5× increased risk compared to non-pregnant women; highest in postpartum period (first 6 weeks). D-dimer is elevated physiologically and unreliable for exclusion. Wells score interpretation is unchanged but threshold for imaging should be lower.

Preferred anticoagulant: Enoxaparin 1 mg/kg SC BD — DOACs are contraindicated in pregnancy and breastfeeding. Warfarin can be used in the second trimester if LMWH is not feasible but is teratogenic in the first trimester.

Meralgia paraesthetica: Increased risk due to weight gain and altered gait; usually self-limiting postpartum.

Sciatica: Common in the third trimester due to lumbar lordosis and foetal weight. Conservative management preferred; paracetamol and short courses of paracetamol/codeine combinations acceptable. NSAIDs are contraindicated after 30 weeks gestation (premature ductus arteriosus closure).

🩺 Compression stockings may reduce DVT risk in pregnancy with additional risk factors. Perform pre-delivery DVT risk assessment per ACSQHC guidelines.

👶 Paediatrics

Consider differentials: In children, leg pain may indicate Perthes disease (4–8 years), slipped capital femoral epiphysis (SCFE, 10–16 years), Osgood-Schlatter disease (active adolescents), osteomyelitis, septic arthritis, juvenile idiopathic arthritis, or leukaemia.

Compartment syndrome: High-risk with supracondylar humerus fractures and displaced forearm fractures. Children cannot reliably report symptoms — rely on clinical signs and have a low threshold for pressure measurement.

DVT: Rare in children; consider central venous catheter-related thrombosis, inherited thrombophilia, or nephrotic syndrome. Enoxaparin 1.5 mg/kg SC BD (neonates) or age-adjusted dosing (children) — consult paediatric haematology.

Growing pains: Bilateral, non-specific leg pain in children aged 3–12 years, occurring in the evening/night, resolving by morning, with normal examination. Diagnosis of exclusion — reassure parents and advise stretching, warm compresses, and paracetamol PRN.

🩺 Any child with persistent or worsening leg pain, night pain, weight loss, or systemic symptoms requires urgent investigation (FBE, ESR, CRP, plain X-ray) and consideration of malignancy or infection.

👴 Elderly (≥65 years)

Polymyalgia rheumatica (PMR): New-onset bilateral hip and shoulder girdle pain and stiffness in patients >50 years; ESR/CRP markedly elevated. Responds dramatically to low-dose prednisolone (15–20 mg daily). Check ESR >40 mm/hr. Refer for temporal artery biopsy if GCA suspected.

PAD prevalence: ~12% of Australians ≥65 years. Often asymptomatic or atypical presentations. Routine ABI screening is not currently recommended in Australia but should be performed in patients with cardiovascular risk factors.

Falls risk: Leg pain contributes to falls in the elderly — assess and address contributing factors (peripheral neuropathy, proprioception, medication side effects including sedatives, antihypertensives).

D-dimer false positives: Use age-adjusted D-dimer cutoffs (>50 years: age × 10 ng/mL) to improve specificity without compromising safety.

🩺 Polypharmacy review is essential — statin-induced myopathy, peripheral neuropathy from metformin or chemotherapy agents, and medication-induced oedema are common contributors to leg pain in the elderly.

🫘 Renal Impairment

DVT treatment: eGFR <30: dose-adjust enoxaparin (1 mg/kg SC daily with anti-Xa monitoring). eGFR <15: prefer unfractionated heparin (UFH) infusion (IV) with APTT monitoring. DOACs may be used with caution in eGFR 15–49 — rivaroxaban and apixaban have best evidence in moderate CKD.

Restless legs syndrome: Common in dialysis patients (up to 30% prevalence). Iron supplementation if ferritin <200 µg/L; gabapentin 200–300 mg post-dialysis is first-line. Avoid pregabalin accumulation.

Calciphylaxis: Rare but life-threatening cause of leg pain in patients with end-stage kidney disease — painful, violaceous, necrotic skin lesions. Requires urgent nephrology referral.

🩺 Avoid NSAIDs in CKD (eGFR <60). Paracetamol and tramadol (dose-adjusted) are preferred analgesics. Gabapentin requires renal dose adjustment.

🛡️ Immunocompromised

Broadened differential: Consider atypical infections (non-tuberculous mycobacteria, fungal osteomyelitis), opportunistic causes of cellulitis, and disseminated strongyloides in returned travellers from tropical regions.

Necrotising fasciitis: Higher incidence in immunocompromised; may present atypically without classic skin changes. Low threshold for surgical exploration. Empirical antibiotics: Piperacillin-tazobactam 4.5 g IV TDS + clindamycin 600 mg IV TDS + vancomycin IV (dose per local protocol).

HIV: Consider HIV-associated distal symmetric polyneuropathy (most common neurological complication); antiretroviral toxicity (didanosine, stavudine — largely historical).

🩺 In immunosuppressed patients (transplant, biologics, chemotherapy), any unexplained leg pain requires a lower threshold for investigation including blood cultures, MRI with contrast, and early specialist referral.

🫁 Hepatic Impairment

Anticoagulation: Avoid DOACs in severe hepatic impairment (Child-Pugh C). Warfarin sensitivity is increased in liver disease — INR monitoring is mandatory. LMWH is preferred but monitor anti-Xa levels as clearance may be altered.

Coagulopathy: Patients with cirrhosis may paradoxically have both bleeding and thrombotic risk (rebalanced haemostasis). DVT management requires haematology input.

Hepatic myopathy: Chronic liver disease may cause proximal muscle wasting and weakness — assess as a contributor to functional leg pain.

🩺 Avoid statins in active liver disease or unexplained persistent transaminase elevation >3× ULN. In stable chronic liver disease, statins may be used cautiously with monitoring.

Monitoring

Initial presentation

Full history and examination. Apply Wells score if DVT suspected. Document pulse status and ABI if PAD suspected. Order targeted investigations. Provide safety-net advice and arrange follow-up.

1–2 weeks

Review D-dimer and ultrasound results. For sciatica: assess response to conservative management. For DVT: confirm treatment adherence and assess for bleeding. For PAD: commence supervised exercise programme.

4–6 weeks

Sciatica: if not improving, consider gabapentinoid initiation, physiotherapy escalation, or MRI referral. DVT: repeat compression ultrasound if clinical suspicion remains. PAD: reassess exercise tolerance and ABI response.

3 months

DVT: reassess anticoagulation duration (provoked = cease; unprovoked = consider extended therapy). PAD: assess response to medical therapy. Sciatica: surgical referral if intractable. Post-fasciotomy: wound review and rehabilitation assessment.

6–12 months

DVT: screen for post-thrombotic syndrome (Villalta score). PAD: annual cardiovascular risk review. Vascular: duplex surveillance if endovascular intervention performed. Chronic neuropathic pain: review gabapentinoid efficacy and side effects, consider weaning if pain-free >3 months.

Monitoring Requirements for Anticoagulation

Agent	Monitoring	Frequency
Apixaban / Rivaroxaban	FBE, LFTs, eGFR at baseline; renal function every 6–12 months; clinical bleeding assessment	Baseline → 3 months → 6-monthly
Warfarin	INR targeting 2.0–3.0 (standard VTE)	Weekly until stable → 2–4 weekly
Enoxaparin	Anti-Xa levels if renal impairment, extremes of weight, pregnancy	Peak level (4 hrs post-dose) at initiation → as needed

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Australians experience a significantly higher burden of conditions causing leg pain, including diabetes-related peripheral neuropathy, peripheral arterial disease, lower-limb amputation, and delayed presentation of DVT and compartment syndrome. Culturally safe, community-based approaches are essential to improving outcomes.

Diabetes & PAD burden

Aboriginal and Torres Strait Islander Australians are 3.5 times more likely to have diabetes than non-Indigenous Australians (AIHW 2023). Diabetes-related lower-limb amputation rates are 3–6 times higher. Routine foot screening using the Modified Monofilament Test and pedal pulse assessment should be integrated into chronic disease management (MBS Item 721/723) at Aboriginal Community Controlled Health Services (ACCHS).

Remote & rural access

Many Aboriginal and Torres Strait Islander Australians live in remote and very remote areas where specialist vascular, orthopaedic, and diagnostic imaging services are limited or absent. Point-of-care ultrasound (POCUS) for DVT assessment and ABI measurement should be available at remote health centres. Telehealth consultation with vascular specialists (MBS Items 99200–99215) is essential for timely triage. Royal Flying Doctor Service (RFDS) and Retrieval Services Australia coordinate emergency evacuation for compartment syndrome and acute limb ischaemia.

Cultural safety

Health assessments should be delivered in a culturally safe environment. Acknowledge that "leg pain" may not be the primary presenting complaint — patients may present with reduced mobility, falls, or avoidance of activity rather than explicitly reporting pain. Use the Acknowledgement of Country and allow time for yarning-based consultation. Ensure same-gender health practitioners are available for examination where preferred. Involve Aboriginal and Torres Strait Islander health workers in care planning and education.

Preventive care

The National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People (3rd edition, RACGP/NACCHO) recommends annual foot checks for all adults with diabetes or cardiovascular risk factors. Vascular risk factor management (smoking cessation, exercise, nutrition) should be integrated with existing chronic disease programmes at ACCHS. Consider community-based exercise programmes that are culturally appropriate and locally led.

Social determinants

Overcrowded housing, limited access to healthy food, and lower health literacy contribute to delayed presentation and poorer outcomes. Acknowledge and address social determinants of health in care plans. Referral to Aboriginal and Torres Strait Islander liaison officers, social workers, and community support services is recommended for all patients requiring extended treatment (e.g., prolonged anticoagulation, post-surgical rehabilitation).

📚 References

1. Royal Australian College of General Practitioners (RACGP). Guideline for the management of acute and chronic low back pain in adults. Melbourne: RACGP; 2023. Available from: racgp.org.au
2. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE guideline NG59. London: NICE; 2016 (updated 2023).
3. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
4. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13):1227–1235.
5. Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226–3256.
6. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. Australian clinical guidelines for the diagnosis and management of peripheral arterial disease. Melbourne: NHF; 2022.
7. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: supplementary data tables. Canberra: AIHW; 2023.
8. Royal Australian College of General Practitioners (RACGP); National Aboriginal Community Controlled Health Organisation (NACCHO). National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People. 3rd ed. Melbourne: RACGP; 2018.
9. Via AG, Oliva F, Spoliti M, Maffulli N. Acute compartment syndrome. Muscles Ligaments Tendons J. 2015;5(1):18–22.
10. Lane R, Harwood A, Watson L, Greenwood DC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;12(12):CD000990.
11. Peul WC, van Houwelingen HC, van den Hout WB, et al. Surgery versus prolonged conservative treatment for sciatica. N Engl J Med. 2007;356(22):2245–2256.
12. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
13. Caprini JA. Thrombotic risk assessment: a hybrid approach. Semin Thromb Hemost. 2017;43(5):459–465.
14. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):381S–453S.
15. Davies MG, Anaya-Ayala JE. Endovascular techniques for the treatment of lower extremity claudication. Vasc Health Risk Manag. 2015;11:381–394.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).